Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 14/20 | 0.48 |
| ▸ | F13A1 | P00488 | 11/20 | 0.48 |
| ▸ | TGM1 | P22735 | 8/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.43 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23929105 | 0.88 | NPC1 (0.46) | NPC1RAB9A | |
| SCHEMBL6737259 | 0.81 | TGM2 (0.48) | TGM2F13A1TGM1TGFBR1TGM3 | |
| SCHEMBL2252120 | 0.81 | TGM2 (0.63) | TGM2F13A1TGM1 | |
| SCHEMBL23940019 | 0.80 | BRD4 (0.46) | TGM2F13A1TGM1 | |
| SCHEMBL6730443 | 0.77 | PPARG (0.50) | TGM2F13A1TGM1TGM3 | |
| SCHEMBL3898487 | 0.75 | GLA (0.64) | TGM2F13A1TGM1 | |
| SCHEMBL23924021 | 0.75 | KMT2A (0.42) | — | |
| SCHEMBL6733950 | 0.74 | PPARG (0.47) | TGM2F13A1TGM1TGM3 | |
| SCHEMBL13765376 | 0.73 | SMN1; SMN2 (0.46) | TGM2F13A1TGM1 | |
| SCHEMBL23923566 | 0.73 | BRD4 (0.46) | TGM2F13A1TGM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122010912-A | Antiviral 1, 3-dioxoindene compounds | 诺华股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20250188066-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-06-12 | — | — | US | disclosed |
| US-12286423-B2 | Antiviral 1,3-di-oxo-indene compounds | NOVARTIS AG (CH) | 2025-04-29 | — | — | US | disclosed |
| CN-115867545-A | Antiviral 1,3 dioxoindene compounds | 诺华股份有限公司 | 2023-03-28 | — | — | CN | disclosed |
| EP-4139301-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | Novartis AG (CH) | 2023-03-01 | — | — | EP | disclosed |
| WO-2021214080-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | NOVARTIS AG (CH) | 2021-10-28 | — | — | WO | disclosed |
| US-20210323947-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | NOVARTIS AG (CH) | 2021-10-21 | — | — | US | disclosed |
| US-20210323947-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | NOVARTIS AG (CH) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188066-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | IRF3, EIF2AK2, ZC3HAV1 | TGM2 3472/4885F13A1 3604/4885TGM1 2880/4885 |
| US-20210323947-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | IRF3, EIF2AK2, ZC3HAV1 | TGM2 3472/4885F13A1 3604/4885TGM1 2880/4885 |
| US-12286423-B2 | Antiviral 1,3-di-oxo-indene compounds | IRF3, EIF2AK2, ZC3HAV1 | TGM2 3472/4885F13A1 3604/4885TGM1 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.